FibroGen Inc.'s Roxadustat met the primary endpoints in two phase 3 anemia studies in China.
The drug was being evaluated in dialysis-dependent and non-dialysis dependent patients with chronic kidney disease. Both patient types experienced an increase in their hemoglobin levels and achieved the desired effect under the studies.
The data will support a new drug application in China. FibroGen is co-developing the drug with AstraZeneca PLC.
Anemia, a deficiency of red blood cells, common develops in association with the chronic kidney disease.